^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LNK01002

    i
    Other names: LNK01002, LNK-1000318
    Associations

    News

    Trials
    Company:
    Lynk Pharmaceuticals
    Drug class:
    Kinase inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=0, Withdrawn, Lynk Pharmaceuticals Co., Ltd | N=93 --> 0 | Trial completion date: Dec 2023 --> Oct 2022 | Recruiting --> Withdrawn | Trial primary completion date: Oct 2023 --> Oct 2022
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    LNK01002